BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sansal I, Sellers WR. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. JCO 2004;22:2954-63. [DOI: 10.1200/jco.2004.02.141] [Cited by in Crossref: 638] [Cited by in F6Publishing: 286] [Article Influence: 35.4] [Reference Citation Analysis]
Number Citing Articles
1 Shin HJ, Lee KJ, Gil M. Multiomic Analysis of Cereblon Expression and Its Prognostic Value in Kidney Renal Clear Cell Carcinoma, Lung Adenocarcinoma, and Skin Cutaneous Melanoma. J Pers Med 2021;11:263. [PMID: 33916291 DOI: 10.3390/jpm11040263] [Reference Citation Analysis]
2 Allain DC. Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn. 2008;10:383-395. [PMID: 18687797 DOI: 10.2353/jmoldx.2008.070161] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
3 Mo M, Hu X, He W, Zu X, Wang L, Li Y. Identification of key genes and microRNA regulatory network in development and progression of urothelial bladder carcinoma. Transl Androl Urol 2021;10:438-47. [PMID: 33532331 DOI: 10.21037/tau-20-1124] [Reference Citation Analysis]
4 Popova NV, Jücker M. The Role of mTOR Signaling as a Therapeutic Target in Cancer. Int J Mol Sci 2021;22:1743. [PMID: 33572326 DOI: 10.3390/ijms22041743] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
5 Gonzalez-Angulo AM, Blumenschein GR Jr. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 2013;39:313-20. [PMID: 23218708 DOI: 10.1016/j.ctrv.2012.11.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
6 Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, Mazina K, Lin R, Wu J, Fredrickson J, Spoerke JM, Lackner MR, Yan Y, Friedman LS, Kaye SB, Derynck MK, Workman P, de Bono JS. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015;21:77-86. [PMID: 25370471 DOI: 10.1158/1078-0432.CCR-14-0947] [Cited by in Crossref: 181] [Cited by in F6Publishing: 124] [Article Influence: 22.6] [Reference Citation Analysis]
7 de Graeff P, Crijns AP, Ten Hoor KA, Klip HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries EG. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer. 2008;99:341-349. [PMID: 18628764 DOI: 10.1038/sj.bjc.6604471] [Cited by in Crossref: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.6] [Reference Citation Analysis]
8 De Minicis S, Kisseleva T, Francis H, Baroni GS, Benedetti A, Brenner D, Alvaro D, Alpini G, Marzioni M. Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma. Dig Liver Dis 2013;45:450-9. [PMID: 23177172 DOI: 10.1016/j.dld.2012.10.008] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
9 Bianco R, Garofalo S, Rosa R, Damiano V, Gelardi T, Daniele G, Marciano R, Ciardiello F, Tortora G. Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008;98:923-30. [PMID: 18319715 DOI: 10.1038/sj.bjc.6604269] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 6.9] [Reference Citation Analysis]
10 Li JZ, Gao W, Lei WB, Zhao J, Chan JY, Wei WI, Ho WK, Wong TS. MicroRNA 744-3p promotes MMP-9-mediated metastasis by simultaneously suppressing PDCD4 and PTEN in laryngeal squamous cell carcinoma. Oncotarget 2016;7:58218-33. [PMID: 27533461 DOI: 10.18632/oncotarget.11280] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 6.8] [Reference Citation Analysis]
11 Messina MP, Rauktys A, Lee L, Dabora SL. Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779. BMC Pharmacol 2007;7:14. [PMID: 17986349 DOI: 10.1186/1471-2210-7-14] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
12 Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phosphatase activity while decreasing PTEN protein stability by inhibiting casein kinase 2. Mol Cell Biol 2013;33:3091-8. [PMID: 23732914 DOI: 10.1128/MCB.00319-13] [Cited by in Crossref: 106] [Cited by in F6Publishing: 72] [Article Influence: 11.8] [Reference Citation Analysis]
13 Lodish MB, Stratakis CA. The differential diagnosis of familial lentiginosis syndromes. Fam Cancer 2011;10:481-90. [PMID: 21538076 DOI: 10.1007/s10689-011-9446-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
14 Rinker-Schaeffer CW, O'Keefe JP, Welch DR, Theodorescu D. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res. 2006;12:3882-3889. [PMID: 16818682 DOI: 10.1158/1078-0432.CCR-06-1014] [Cited by in Crossref: 97] [Cited by in F6Publishing: 52] [Article Influence: 6.5] [Reference Citation Analysis]
15 Wang H, Xu C, Kong X, Li X, Kong X, Wang Y, Ding X, Yang Q. Trail resistance induces epithelial-mesenchymal transition and enhances invasiveness by suppressing PTEN via miR-221 in breast cancer. PLoS One 2014;9:e99067. [PMID: 24905916 DOI: 10.1371/journal.pone.0099067] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
16 Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol 2011;121:455-61. [PMID: 21414654 DOI: 10.1016/j.ygyno.2011.02.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
17 Wen X, Klionsky DJ. At a glance: A history of autophagy and cancer. Semin Cancer Biol 2020;66:3-11. [PMID: 31707087 DOI: 10.1016/j.semcancer.2019.11.005] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
18 Zhang Q, Claret FX. Phosphatases: the new brakes for cancer development? Enzyme Res. 2012;2012:659649. [PMID: 22121480 DOI: 10.1155/2012/659649] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
19 Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers. 2013;35:369-387. [PMID: 24191129 DOI: 10.1155/2013/451248] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 8.4] [Reference Citation Analysis]
20 Agarwal S, Bell CM, Rothbart SB, Moran RG. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. J Biol Chem 2015;290:27473-86. [PMID: 26391395 DOI: 10.1074/jbc.M115.665133] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
21 Garcia-Carracedo D, Chen ZM, Qiu W, Huang AS, Tang SM, Hruban RH, Su GH. PIK3CA mutations in mucinous cystic neoplasms of the pancreas. Pancreas. 2014;43:245-249. [PMID: 24518503 DOI: 10.1097/mpa.0000000000000034] [Cited by in Crossref: 45] [Cited by in F6Publishing: 17] [Article Influence: 5.6] [Reference Citation Analysis]
22 Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, Livasy C, Fritchie K, Prat A, Harrell JC, Ewend MG, Carey LA, Miller CR, Anders CK. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 2011;13:R125. [PMID: 22132754 DOI: 10.1186/bcr3071] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
23 Rivière JB, Mirzaa GM, O'Roak BJ, Beddaoui M, Alcantara D, Conway RL, St-Onge J, Schwartzentruber JA, Gripp KW, Nikkel SM. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44:934-940. [PMID: 22729224 DOI: 10.1038/ng.2331] [Cited by in Crossref: 450] [Cited by in F6Publishing: 397] [Article Influence: 45.0] [Reference Citation Analysis]
24 Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J, Liu Y. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 2011;6:e28405. [PMID: 22145042 DOI: 10.1371/journal.pone.0028405] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
25 Gillson J, Abd El-aziz YS, Leck LYW, Jansson PJ, Pavlakis N, Samra JS, Mittal A, Sahni S. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Cancers 2022;14:3528. [DOI: 10.3390/cancers14143528] [Reference Citation Analysis]
26 Chang CJ, Mulholland DJ, Valamehr B, Mosessian S, Sellers WR, Wu H. PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppression. Mol Cell Biol 2008;28:3281-9. [PMID: 18332125 DOI: 10.1128/MCB.00310-08] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 6.9] [Reference Citation Analysis]
27 Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L, Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C, Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J, White KP. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell 2014;25:455-68. [PMID: 24656772 DOI: 10.1016/j.ccr.2014.02.007] [Cited by in Crossref: 97] [Cited by in F6Publishing: 89] [Article Influence: 12.1] [Reference Citation Analysis]
28 Tan AC. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). Thorac Cancer 2020;11:511-8. [PMID: 31989769 DOI: 10.1111/1759-7714.13328] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 18.5] [Reference Citation Analysis]
29 Dituri F, Mazzocca A, Giannelli G, Antonaci S. PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors. Clin Dev Immunol 2011;2011:947858. [PMID: 22046194 DOI: 10.1155/2011/947858] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
30 Shen-Li H, Koujak S, Szablocs M, Parsons R. Reduction of Pten dose leads to neoplastic development in multiple organs of Pten (shRNA) mice. Cancer Biol Ther 2010;10:1194-200. [PMID: 20980828 DOI: 10.4161/cbt.10.11.13814] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
31 Persad A, Venkateswaran G, Hao L, Garcia ME, Yoon J, Sidhu J, Persad S. Active β-catenin is regulated by the PTEN/PI3 kinase pathway: a role for protein phosphatase PP2A. Genes Cancer 2016;7:368-82. [PMID: 28191283 DOI: 10.18632/genesandcancer.128] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
32 Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007;9:271-8. [PMID: 17460771 DOI: 10.1593/neo.07124] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 5.7] [Reference Citation Analysis]
33 Post KL, Belmadani M, Ganguly P, Meili F, Dingwall R, McDiarmid TA, Meyers WM, Herrington C, Young BP, Callaghan DB, Rogic S, Edwards M, Niciforovic A, Cau A, Rankin CH, O'Connor TP, Bamji SX, Loewen CJR, Allan DW, Pavlidis P, Haas K. Multi-model functionalization of disease-associated PTEN missense mutations identifies multiple molecular mechanisms underlying protein dysfunction. Nat Commun 2020;11:2073. [PMID: 32350270 DOI: 10.1038/s41467-020-15943-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
34 Sanada A, Yamada T, Hasegawa S, Ishii Y, Hasebe Y, Iwata Y, Arima M, Sugiura K, Akamatsu H. Enhanced Type I Collagen Synthesis in Fibroblasts by Dermal Stem/Progenitor Cell-Derived Exosomes. Biol Pharm Bull 2022;45:872-80. [PMID: 35786595 DOI: 10.1248/bpb.b21-01084] [Reference Citation Analysis]
35 Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 2013;32:253-65. [PMID: 23642907 DOI: 10.5732/cjc.013.10057] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 13.5] [Reference Citation Analysis]
36 Zhou SL, Wang LD. Circulating microRNAs: Novel biomarkers for esophageal cancer. World J Gastroenterol 2010; 16(19): 2348-2354 [PMID: 20480519 DOI: 10.3748/wjg.v16.i19.2348] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
37 Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid 2016;11:23-36. [PMID: 27621699 DOI: 10.2147/CE.S98687] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
38 Deruy E, Gosselin K, Vercamer C, Martien S, Bouali F, Slomianny C, Bertout J, Bernard D, Pourtier A, Abbadie C. MnSOD upregulation induces autophagic programmed cell death in senescent keratinocytes. PLoS One 2010;5:e12712. [PMID: 20856861 DOI: 10.1371/journal.pone.0012712] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
39 Legakis I, Syrigos K. Recent advances in molecular diagnosis of thyroid cancer. J Thyroid Res 2011;2011:384213. [PMID: 21603167 DOI: 10.4061/2011/384213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
40 Sforza V, Martinelli E, Ciardiello F, Gambardella V, Napolitano S, Martini G, della Corte C, Cardone C, Ferrara ML, Reginelli A, Liguori G, Belli G, Troiani T. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016; 22(28): 6345-6361 [PMID: 27605871 DOI: 10.3748/wjg.v22.i28.6345] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 64] [Article Influence: 11.3] [Reference Citation Analysis]
41 Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, Zhu YD, Diao Y, Wang AD, Lan Q. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 2008;8:304. [PMID: 18940013 DOI: 10.1186/1471-2407-8-304] [Cited by in Crossref: 72] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
42 Wang Y, Tong Z, Zhang W, Zhang W, Buzdin A, Mu X, Yan Q, Zhao X, Chang HH, Duhon M, Zhou X, Zhao G, Chen H, Li X. FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. Front Oncol 2021;11:683419. [PMID: 34164344 DOI: 10.3389/fonc.2021.683419] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
43 Wendel HG, Malina A, Zhao Z, Zender L, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. Cancer Res 2006;66:7639-46. [PMID: 16885364 DOI: 10.1158/0008-5472.CAN-06-0419] [Cited by in Crossref: 78] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
44 Zhang B, Cao J, Zhou Q, Chen JY, Zou XP. Correlation between PTEN protein expression and clinicopathological features in the precancerous lesions and early gastric cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(32): 3626-3630 [DOI: 10.11569/wcjd.v16.i32.3626] [Reference Citation Analysis]
45 Hamann BL, Blind RD. Nuclear phosphoinositide regulation of chromatin. J Cell Physiol 2018;233:107-23. [PMID: 28256711 DOI: 10.1002/jcp.25886] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
46 Okazaki M, Horimoto Y, Tanabe M, Ichikawa Y, Tokuda E, Arakawa A, Kobayashi T, Saito M. Predictive markers for efficacy of everolimus plus exemestane in patients with luminal HER2-negative metastatic breast cancer. Med Oncol. 2018;35:48. [PMID: 29520681 DOI: 10.1007/s12032-018-1112-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
47 Chong X, Chen J, Zheng N, Zhou Z, Hai Y, Chen S, Zhang Y, Yu Q, Yu S, Chen Z, Bao W, Quan M, Chen ZS, Zhan Y, Gao Y. PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN. Mol Cancer 2022;21:118. [PMID: 35619132 DOI: 10.1186/s12943-022-01531-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Xu N, Lao Y, Zhang Y, Gillespie DA. Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012;2012:951724. [PMID: 22481935 DOI: 10.1155/2012/951724] [Cited by in Crossref: 118] [Cited by in F6Publishing: 142] [Article Influence: 11.8] [Reference Citation Analysis]
49 Kolanska K, Bendifallah S, Canlorbe G, Mekinian A, Touboul C, Aractingi S, Chabbert-Buffet N, Daraï E. Role of miRNAs in Normal Endometrium and in Endometrial Disorders: Comprehensive Review. J Clin Med 2021;10:3457. [PMID: 34441754 DOI: 10.3390/jcm10163457] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Wang X, Li G, Koul S, Ohki R, Maurer M, Borczuk A, Halmos B. PHLDA2 is a key oncogene-induced negative feedback inhibitor of EGFR/ErbB2 signaling via interference with AKT signaling. Oncotarget 2018;9:24914-26. [PMID: 29861842 DOI: 10.18632/oncotarget.3674] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
51 Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012;32:190-5. [PMID: 22737980 DOI: 10.3109/10799893.2012.695798] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
52 Nguyen SA, Walker D, Gillespie MB, Gutkind JS, Day TA. mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma. Curr Treat Options Oncol 2012;13:71-81. [PMID: 22282394 DOI: 10.1007/s11864-011-0180-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
53 Furuya F, Hanover JA, Cheng SY. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc Natl Acad Sci U S A 2006;103:1780-5. [PMID: 16446424 DOI: 10.1073/pnas.0510849103] [Cited by in Crossref: 113] [Cited by in F6Publishing: 107] [Article Influence: 7.1] [Reference Citation Analysis]
54 Mishra RR, Chaudhary JK, Bajaj GD, Rath PC. A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human and mouse tissues, strongly inhibits cell growth in HeLa cells. PLoS One 2011;6:e28433. [PMID: 22164291 DOI: 10.1371/journal.pone.0028433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
55 Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia 2012;17:205-16. [PMID: 22865098 DOI: 10.1007/s10911-012-9264-2] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
56 Khew-Goodall Y, Goodall GJ. Stromal miR-320 keeps an oncogenic secretome in check. Nat Cell Biol. 2012;14:124-125. [PMID: 22298040 DOI: 10.1038/ncb2431] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
57 Sozopoulos E, Litsiou H, Voutsinas G, Mitsiades N, Anagnostakis N, Tseva T, Patsouris E, Tseleni-Balafouta S. Mutational and immunohistochemical study of the PI3K/Akt pathway in papillary thyroid carcinoma in Greece. Endocr Pathol 2010;21:90-100. [PMID: 20186503 DOI: 10.1007/s12022-010-9112-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
58 Goebbels S, Oltrogge JH, Kemper R, Heilmann I, Bormuth I, Wolfer S, Wichert SP, Möbius W, Liu X, Lappe-Siefke C, Rossner MJ, Groszer M, Suter U, Frahm J, Boretius S, Nave KA. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J Neurosci 2010;30:8953-64. [PMID: 20592216 DOI: 10.1523/JNEUROSCI.0219-10.2010] [Cited by in Crossref: 198] [Cited by in F6Publishing: 152] [Article Influence: 16.5] [Reference Citation Analysis]
59 Pham DDM, Guhan S, Tsao H. KIT and Melanoma: Biological Insights and Clinical Implications. Yonsei Med J. 2020;61:562-571. [PMID: 32608199 DOI: 10.3349/ymj.2020.61.7.562] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
60 Krymskaya VP, Goncharova EA. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects. Cell Cycle 2009;8:403-13. [PMID: 19177005 DOI: 10.4161/cc.8.3.7555] [Cited by in F6Publishing: 61] [Reference Citation Analysis]
61 Wang X, Huang H, Young KH. The PTEN tumor suppressor gene and its role in lymphoma pathogenesis. Aging (Albany NY) 2015;7:1032-49. [PMID: 26655726 DOI: 10.18632/aging.100855] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 5.7] [Reference Citation Analysis]
62 Tan M, Xu J, Siddiqui J, Feng F, Sun Y. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis. Mol Cancer 2016;15:81. [PMID: 27955654 DOI: 10.1186/s12943-016-0567-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
63 Gen Y, Yasui K, Nishikawa T, Yoshikawa T. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci. 2013;104:810-816. [PMID: 23510069 DOI: 10.1111/cas.12155] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
64 Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010;11:537-561. [PMID: 21532838 DOI: 10.2174/138920210793175895] [Cited by in Crossref: 815] [Cited by in F6Publishing: 771] [Article Influence: 74.1] [Reference Citation Analysis]
65 Gosselin K, Deruy E, Martien S, Vercamer C, Bouali F, Dujardin T, Slomianny C, Houel-Renault L, Chelli F, De Launoit Y, Abbadie C. Senescent keratinocytes die by autophagic programmed cell death. Am J Pathol 2009;174:423-35. [PMID: 19147823 DOI: 10.2353/ajpath.2009.080332] [Cited by in Crossref: 73] [Cited by in F6Publishing: 63] [Article Influence: 5.6] [Reference Citation Analysis]
66 Lieberman DE, Hallgrímsson B, Liu W, Parsons TE, Jamniczky HA. Spatial packing, cranial base angulation, and craniofacial shape variation in the mammalian skull: testing a new model using mice. J Anat 2008;212:720-35. [PMID: 18510502 DOI: 10.1111/j.1469-7580.2008.00900.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 82] [Article Influence: 6.9] [Reference Citation Analysis]
67 Xia S, Lu Y, Wang J, He C, Hong S, Serhan CN, Kang JX. Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proc Natl Acad Sci U S A 2006;103:12499-504. [PMID: 16888035 DOI: 10.1073/pnas.0605394103] [Cited by in Crossref: 103] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
68 Cloughesy TF, Mischel PS. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res 2011;17:6-11. [PMID: 21208902 DOI: 10.1158/1078-0432.CCR-09-2268] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
69 Konopka B, Janiec-Jankowska A, Czapczak D, Paszko Z, Bidziński M, Olszewski W, Goluda C. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J Cancer Res Clin Oncol. 2007;133:361-371. [PMID: 17219201 DOI: 10.1007/s00432-006-0179-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
70 Fiandalo MV, Wu W, Mohler JL. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets 2013;14:420-40. [PMID: 23565755 DOI: 10.2174/1389450111314040004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
71 Zhang B, Zhang X, Jin M, Hu L, Zang M, Qiu W, Wang S, Liu B, Liu S, Guo D. CagA increases DNA methylation and decreases PTEN expression in human gastric cancer. Mol Med Rep. 2019;19:309-319. [PMID: 30431097 DOI: 10.3892/mmr.2018.9654] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
72 Showkat M, Beigh MA, Andrabi KI. mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions. Mol Biol Int 2014;2014:686984. [PMID: 25505994 DOI: 10.1155/2014/686984] [Cited by in Crossref: 104] [Cited by in F6Publishing: 92] [Article Influence: 13.0] [Reference Citation Analysis]
73 Zhao JJ, Liu Z, Wang L, Shin E, Loda MF, Roberts TM. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 2005;102:18443-8. [PMID: 16339315 DOI: 10.1073/pnas.0508988102] [Cited by in Crossref: 247] [Cited by in F6Publishing: 241] [Article Influence: 14.5] [Reference Citation Analysis]
74 Li Y, Wang H, Muffat J, Cheng AW, Orlando DA, Lovén J, Kwok SM, Feldman DA, Bateup HS, Gao Q, Hockemeyer D, Mitalipova M, Lewis CA, Vander Heiden MG, Sur M, Young RA, Jaenisch R. Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 2013;13:446-58. [PMID: 24094325 DOI: 10.1016/j.stem.2013.09.001] [Cited by in Crossref: 202] [Cited by in F6Publishing: 186] [Article Influence: 25.3] [Reference Citation Analysis]
75 Fan HY, Liu Z, Paquet M, Wang J, Lydon JP, DeMayo FJ, Richards JS. Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. Cancer Res 2009;69:6463-72. [PMID: 19679546 DOI: 10.1158/0008-5472.CAN-08-3363] [Cited by in Crossref: 63] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
76 Sun Z, Chen C, Su Y, Wang W, Yang S, Zhou Q, Wang G, Li Z, Song J, Zhang Z, Yuan W, Liu J. Regulatory mechanisms and clinical perspectives of circRNA in digestive system neoplasms. J Cancer 2019;10:2885-91. [PMID: 31281465 DOI: 10.7150/jca.31167] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
77 Moseley RH. Progress in understanding the pathogenesis of nonalcoholic fatty liver disease. Hepatology 2005;41:204-6. [PMID: 15619243 DOI: 10.1002/hep.20558] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
78 Oliveira JC, Souza KK, Dias MM, Faria MC, Ropelle ER, Flores MB, Ueno M, Velloso LA, Saad ST, Saad MJ, Carvalheira JB. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. J Cancer Res Clin Oncol 2008;134:833-9. [PMID: 18264722 DOI: 10.1007/s00432-008-0359-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
79 Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007;447:966-71. [PMID: 17515920 DOI: 10.1038/nature05886] [Cited by in Crossref: 274] [Cited by in F6Publishing: 284] [Article Influence: 18.3] [Reference Citation Analysis]
80 Ohta H, Nordahl CW, Iosif AM, Lee A, Rogers S, Amaral DG. Increased Surface Area, but not Cortical Thickness, in a Subset of Young Boys With Autism Spectrum Disorder. Autism Res 2016;9:232-48. [PMID: 26184828 DOI: 10.1002/aur.1520] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 5.1] [Reference Citation Analysis]
81 Drucker A, Zhou C, Seevanayagam S, Weinberg L. Left atrial cavernous haemangioma presenting with cardiac tamponade in a patient with Cowden syndrome. BMJ Case Rep 2019;12:e229741. [PMID: 31289165 DOI: 10.1136/bcr-2019-229741] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Matsuoka S, Shibata T, Ueda M. Asymmetric PTEN distribution regulated by spatial heterogeneity in membrane-binding state transitions. PLoS Comput Biol 2013;9:e1002862. [PMID: 23326224 DOI: 10.1371/journal.pcbi.1002862] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
83 Walkowski B, Kleibert M, Majka M, Wojciechowska M. Insight into the Role of the PI3K/Akt Pathway in Ischemic Injury and Post-Infarct Left Ventricular Remodeling in Normal and Diabetic Heart. Cells 2022;11:1553. [DOI: 10.3390/cells11091553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Han Y, Hou L, Zhao B, Gao L, Li S. Risk Factors for Neck Nodal Metastasis in Papillary Thyroid Cancer With BRAF V600E Mutation. Front Endocrinol 2022;13:884428. [DOI: 10.3389/fendo.2022.884428] [Reference Citation Analysis]
85 Samad N, Younes A. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther 2010;3:167-78. [PMID: 20856791 DOI: 10.2147/ott.s8147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
86 Huang CH, Mandelker D, Gabelli SB, Amzel LM. Insights into the oncogenic effects of PIK3CA mutations from the structure of p110alpha/p85alpha. Cell Cycle 2008;7:1151-6. [PMID: 18418043 DOI: 10.4161/cc.7.9.5817] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 4.3] [Reference Citation Analysis]
87 Ariyama J, Suyama M, Ogawa K, Ikari T, Nagaiwa J, Fujii D, Tsuchida A. The detection and prognosis of small pancreatic carcinoma. Int J Pancreatol. 1990;7:37-47. [PMID: 1964473 DOI: 10.1038/nrd2926] [Cited by in Crossref: 1691] [Cited by in F6Publishing: 1605] [Article Influence: 54.5] [Reference Citation Analysis]
88 Upton DH, Walters KA, Allavena RE, Jimenez M, Desai R, Handelsman DJ, Allan CM. Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice. Horm Cancer 2016;7:316-26. [PMID: 27506975 DOI: 10.1007/s12672-016-0272-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
89 Peralta-Zaragoza O, Deas J, Meneses-Acosta A, De la O-Gómez F, Fernández-Tilapa G, Gómez-Cerón C, Benítez-Boijseauneau O, Burguete-García A, Torres-Poveda K, Bermúdez-Morales VH, Madrid-Marina V, Rodríguez-Dorantes M, Hidalgo-Miranda A, Pérez-Plasencia C. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells. BMC Cancer 2016;16:215. [PMID: 26975392 DOI: 10.1186/s12885-016-2231-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 7.3] [Reference Citation Analysis]
90 Cai J, Xu L, Tang H, Yang Q, Yi X, Fang Y, Zhu Y, Wang Z. The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis. Oncologist 2014;19:528-35. [PMID: 24718516 DOI: 10.1634/theoncologist.2013-0333] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
91 Ágoston EI, Micsik T, Ács B, Fekete K, Hahn O, Baranyai Z, Dede K, Bodoky G, Bursics A, Kulka J, Krenács T, Győrffy B, Harsányi L, Szász AM. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity. Diagn Pathol 2016;11:61. [PMID: 27392434 DOI: 10.1186/s13000-016-0508-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Westin JR. Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin Lymphoma Myeloma Leuk 2014;14:335-42. [PMID: 24650973 DOI: 10.1016/j.clml.2014.01.007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
93 Segarra M, Lozano E, Corbera-Bellalta M, Vilardell C, Cibeira MT, Esparza J, Izco N, Bladé J, Cid MC. Thalidomide decreases gelatinase production by malignant B lymphoid cell lines through disruption of multiple integrin-mediated signaling pathways. Haematologica 2010;95:456-63. [PMID: 19815837 DOI: 10.3324/haematol.2009.006395] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
94 Dhakal A, Acharya L, O'Regan R, Gandhi S, Falkson C. PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer. Int J Mol Sci 2021;22:11878. [PMID: 34769309 DOI: 10.3390/ijms222111878] [Reference Citation Analysis]
95 Ying Z, Haiyan G, Haidong G. BAG5 regulates PTEN stability in MCF-7 cell line. BMB Rep 2013;46:490-4. [PMID: 24148769 DOI: 10.5483/bmbrep.2013.46.10.268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
96 Giunti S, Antonelli A, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013;2013:803171. [PMID: 23509459 DOI: 10.1155/2013/803171] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
97 Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129-139. [PMID: 17218260 DOI: 10.1016/j.cell.2006.11.039] [Cited by in Crossref: 466] [Cited by in F6Publishing: 457] [Article Influence: 31.1] [Reference Citation Analysis]
98 Rexer BN, Engelman JA, Arteaga CL. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009;8:18-22. [PMID: 19106609 DOI: 10.4161/cc.8.1.7324] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.2] [Reference Citation Analysis]
99 Lu D, Han C, Wu T. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression. Gastroenterology 2011;140:2084-94. [PMID: 21354147 DOI: 10.1053/j.gastro.2011.02.056] [Cited by in Crossref: 18] [Cited by in F6Publishing: 63] [Article Influence: 1.6] [Reference Citation Analysis]
100 Smyth LM, Monson KR, Jhaveri K, Drilon A, Li BT, Abida W, Iyer G, Gerecitano JF, Gounder M, Harding JJ, Voss MH, Makker V, Ho AL, Razavi P, Iasonos A, Bialer P, Lacouture ME, Teitcher JB, Erinjeri JP, Katabi N, Fury MG, Hyman DM. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel. Invest New Drugs 2017;35:742-50. [PMID: 28281183 DOI: 10.1007/s10637-017-0445-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
101 Benesh EC, Humphrey PA, Wang Q, Moley KH. Maternal high-fat diet induces hyperproliferation and alters Pten/Akt signaling in prostates of offspring. Sci Rep 2013;3:3466. [PMID: 24322661 DOI: 10.1038/srep03466] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
102 Liu D, Hou P, Liu Z, Wu G, Xing M. Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res 2009;69:7311-9. [PMID: 19706758 DOI: 10.1158/0008-5472.CAN-09-1077] [Cited by in Crossref: 60] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
103 Anusic S, Clemens RK, Meier TO, Amann-Vesti BR. Assessment of PTEN-associated vascular malformations in a patient with Bannayan-Riley-Ruvalcaba syndrome. BMJ Case Rep 2016;2016:bcr2016215188. [PMID: 27358095 DOI: 10.1136/bcr-2016-215188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
104 Landis J, Shaw LM. Insulin receptor substrate 2-mediated phosphatidylinositol 3-kinase signaling selectively inhibits glycogen synthase kinase 3β to regulate aerobic glycolysis. J Biol Chem 2014;289:18603-13. [PMID: 24811175 DOI: 10.1074/jbc.M114.564070] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
105 Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS. AKT Inhibition in Solid Tumors With AKT1 Mutations. J Clin Oncol 2017;35:2251-9. [PMID: 28489509 DOI: 10.1200/JCO.2017.73.0143] [Cited by in Crossref: 145] [Cited by in F6Publishing: 97] [Article Influence: 29.0] [Reference Citation Analysis]
106 Mecca C, Giambanco I, Bruscoli S, Bereshchenko O, Fioretti B, Riccardi C, Donato R, Arcuri C. PP242 Counteracts Glioblastoma Cell Proliferation, Migration, Invasiveness and Stemness Properties by Inhibiting mTORC2/AKT. Front Cell Neurosci 2018;12:99. [PMID: 29692710 DOI: 10.3389/fncel.2018.00099] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 5.5] [Reference Citation Analysis]
107 Davidson L, Maccario H, Perera NM, Yang X, Spinelli L, Tibarewal P, Glancy B, Gray A, Weijer CJ, Downes CP. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene. 2010;29:687-697. [PMID: 19915616 DOI: 10.1038/onc.2009.384] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 6.8] [Reference Citation Analysis]
108 Mohammed SA. Intrinsic radio-sensitivity of tumours to low let radiations: a mathematical model in LQ formalism. Med Hypotheses 2013;81:1041-5. [PMID: 24182870 DOI: 10.1016/j.mehy.2013.09.031] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Park DJ, Wallick CJ, Martyn KD, Lau AF, Jin C, Warn-Cramer BJ. Akt phosphorylates Connexin43 on Ser373, a "mode-1" binding site for 14-3-3. Cell Commun Adhes 2007;14:211-26. [PMID: 18163231 DOI: 10.1080/15419060701755958] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
110 Villaruz LC, Burns TF, Ramfidis VS, Socinski MA. Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013;34:822-36. [PMID: 24258572 DOI: 10.1055/s-0033-1358552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
111 Goodwin CR, Lal B, Ho S, Woodard CL, Zhou X, Taeger A, Xia S, Laterra J. PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anticancer Drugs 2011;22:905-12. [PMID: 21654317 DOI: 10.1097/CAD.0b013e3283484750] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
112 Du Y, Zhang YW, Pu R, Han X, Hu JP, Zhang HW, Wang HY, Cao GW. Phosphatase and tensin homologue genetic polymorphisms and their interactions with viral mutations on the risk of hepatocellular carcinoma. Chin Med J (Engl) 2015;128:1005-13. [PMID: 25881591 DOI: 10.4103/0366-6999.155057] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
113 Cui W, Gu F, Hu KQ. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 2009; 15(16): 1943-1950 [PMID: 19399925 DOI: 10.3748/wjg.15.1943] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
114 Sauvageot CM, Weatherbee JL, Kesari S, Winters SE, Barnes J, Dellagatta J, Ramakrishna NR, Stiles CD, Kung AL, Kieran MW, Wen PY. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009;11:109-21. [PMID: 18682579 DOI: 10.1215/15228517-2008-060] [Cited by in Crossref: 81] [Cited by in F6Publishing: 70] [Article Influence: 5.8] [Reference Citation Analysis]
115 Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2005;102:10238-43. [PMID: 16006513 DOI: 10.1073/pnas.0504378102] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
116 Roccaro AM, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010;115:559-69. [PMID: 19965685 DOI: 10.1182/blood-2009-07-235747] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 6.2] [Reference Citation Analysis]
117 Hendricks LA, Schuurs-hoeijmakers J, Spier I, Haadsma M, Eijkelenboom A, Cremer K, Mensenkamp AR, Aretz S, Vos JR, Hoogerbrugge N. Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review. European Journal of Medical Genetics 2022. [DOI: 10.1016/j.ejmg.2022.104533] [Reference Citation Analysis]
118 Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med 2009;133:1775-81. [PMID: 19886711 DOI: 10.5858/133.11.1775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 21] [Article Influence: 0.2] [Reference Citation Analysis]
119 Lu TL, Chang JL, Liang CC, You LR, Chen CM. Tumor spectrum, tumor latency and tumor incidence of the Pten-deficient mice. PLoS One 2007;2:e1237. [PMID: 18043744 DOI: 10.1371/journal.pone.0001237] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
120 Fan HY, Liu Z, Cahill N, Richards JS. Targeted disruption of Pten in ovarian granulosa cells enhances ovulation and extends the life span of luteal cells. Mol Endocrinol 2008;22:2128-40. [PMID: 18606860 DOI: 10.1210/me.2008-0095] [Cited by in Crossref: 124] [Cited by in F6Publishing: 119] [Article Influence: 8.9] [Reference Citation Analysis]
121 Kurek KC, Howard E, Tennant LB, Upton J, Alomari AI, Burrows PE, Chalache K, Harris DJ, Trenor CC 3rd, Eng C, Fishman SJ, Mulliken JB, Perez-Atayde AR, Kozakewich HP. PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol 2012;36:671-87. [PMID: 22446940 DOI: 10.1097/PAS.0b013e31824dd86c] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
122 Gumuskaya B, Gurel B, Fedor H, Tan HL, Weier CA, Hicks JL, Haffner MC, Lotan TL, De Marzo AM. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion. Prostate Cancer Prostatic Dis 2013;16:209-15. [PMID: 23545904 DOI: 10.1038/pcan.2013.8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
123 Maccario H, Perera NM, Davidson L, Downes CP, Leslie NR. PTEN is destabilized by phosphorylation on Thr366. Biochem J 2007;405:439-44. [PMID: 17444818 DOI: 10.1042/BJ20061837] [Cited by in Crossref: 105] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
124 Sun R, Wang J, Young KH. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies. Crit Rev Oncog 2017;22:527-57. [PMID: 29604930 DOI: 10.1615/CritRevOncog.2017020816] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Neychev V, Sadowski SM, Zhu J, Allgaeuer M, Kilian K, Meltzer P, Kebebew E. Neuroendocrine Tumor of the Pancreas as a Manifestation of Cowden Syndrome: A Case Report. J Clin Endocrinol Metab 2016;101:353-8. [PMID: 26678657 DOI: 10.1210/jc.2015-3684] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
126 Zhang M, Tao Z, Gao L, Chen F, Ye Y, Xu S, Huang W, Li X. Toosendanin inhibits colorectal cancer cell growth through the Hedgehog pathway by targeting Shh. Drug Dev Res 2022. [PMID: 35656621 DOI: 10.1002/ddr.21951] [Reference Citation Analysis]
127 Huang Y, Mao X, Boyce T, Zhu GZ. Dispensable role of PTEN in mouse spermatogenesis. Cell Biol Int 2011;35:905-8. [PMID: 21524277 DOI: 10.1042/CBI20110161] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
128 Wang L, Liu R, Li W, Chen C, Katoh H, Chen GY, McNally B, Lin L, Zhou P, Zuo T, Cooney KA, Liu Y, Zheng P. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009;16:336-46. [PMID: 19800578 DOI: 10.1016/j.ccr.2009.08.016] [Cited by in Crossref: 143] [Cited by in F6Publishing: 148] [Article Influence: 11.0] [Reference Citation Analysis]
129 Bermúdez Brito M, Goulielmaki E, Papakonstanti EA. Focus on PTEN Regulation. Front Oncol 2015;5:166. [PMID: 26284192 DOI: 10.3389/fonc.2015.00166] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 9.0] [Reference Citation Analysis]
130 Sfakianos JP, Lin Gellert L, Maschino A, Gotto GT, Kim PH, Al-Ahmadie H, Bochner BH. The role of PTEN tumor suppressor pathway staining in carcinoma in situ of the bladder. Urol Oncol. 2014;32:657-662. [PMID: 24840867 DOI: 10.1016/j.urolonc.2014.02.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
131 Schick J, Ritchie RP, Restini C. Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches. Breast Cancer (Auckl) 2021;15:1178223421995854. [PMID: 33994789 DOI: 10.1177/1178223421995854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
132 Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y, Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci 2013;9:435-43. [PMID: 23678293 DOI: 10.7150/ijbs.6087] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 13.7] [Reference Citation Analysis]
133 Roth SG, Feldman MJ, Borst AJ, Froehler MT. Formation of a de novo intracranial arteriovenous fistula in a child with PTEN hamartoma tumor syndrome. Childs Nerv Syst 2021. [PMID: 34409504 DOI: 10.1007/s00381-021-05321-6] [Reference Citation Analysis]
134 Żyła MM, Wilczyński JR, Kostrzewa M, Księżakowska-Łakoma K, Nowak M, Stachowiak G, Szyłło K, Stetkiewicz T. The significance of markers in the diagnosis of endometrial cancer. Prz Menopauzalny 2016;15:176-85. [PMID: 27980530 DOI: 10.5114/pm.2016.63500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
135 Kalachand R, Hennessy BT, Markman M. Molecular targeted therapy in ovarian cancer: what is on the horizon? Drugs 2011;71:947-67. [PMID: 21668036 DOI: 10.2165/11591740-000000000-00000] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
136 Hollander MC, Balogh AR, Liwanag J, Han W, Linnoila RI, Anver MR, Dennis PA. Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. Neoplasia 2008;10:866-72. [PMID: 18683321 DOI: 10.1593/neo.08406] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
137 Liu S, Jia J, Zhou H, Zhang C, Liu L, Liu J, Lu L, Li X, Kang Y, Lou Y, Cai Z, Ren Y, Kong X, Feng S. PTEN modulates neurites outgrowth and neuron apoptosis involving the PI3K/Akt/mTOR signaling pathway. Mol Med Rep 2019;20:4059-66. [PMID: 31702028 DOI: 10.3892/mmr.2019.10670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
138 Yi T, Lindner D. The role and target potential of protein tyrosine phosphatases in cancer. Curr Oncol Rep 2008;10:114-21. [PMID: 18377824 DOI: 10.1007/s11912-008-0019-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
139 Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 2015;6:15035-49. [PMID: 25909227 DOI: 10.18632/oncotarget.3729] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 10.3] [Reference Citation Analysis]
140 Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27:857-871. [PMID: 19164214 DOI: 10.1200/jco.2008.17.6297] [Cited by in Crossref: 123] [Cited by in F6Publishing: 75] [Article Influence: 9.5] [Reference Citation Analysis]
141 Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N, Langholz B, Sherman ME. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68:6014-20. [PMID: 18632658 DOI: 10.1158/0008-5472.CAN-08-1154] [Cited by in Crossref: 53] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
142 Wang Y, Cheng A, Mattson MP. The PTEN phosphatase is essential for long-term depression of hippocampal synapses. Neuromolecular Med 2006;8:329-36. [PMID: 16775384 DOI: 10.1385/NMM:8:3:329] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
143 Ebbesen SH, Scaltriti M, Bialucha CU, Morse N, Kastenhuber ER, Wen HY, Dow LE, Baselga J, Lowe SW. Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 2016;113:3030-5. [PMID: 26929372 DOI: 10.1073/pnas.1523693113] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
144 Ghebeh H, Al-Khaldi S, Olabi S, Al-Dhfyan A, Al-Mohanna F, Barnawi R, Tulbah A, Al-Tweigeri T, Ajarim D, Al-Alwan M. Fascin is involved in the chemotherapeutic resistance of breast cancer cells predominantly via the PI3K/Akt pathway. Br J Cancer 2014;111:1552-61. [PMID: 25117814 DOI: 10.1038/bjc.2014.453] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 4.5] [Reference Citation Analysis]
145 Naguib A, Trotman LC. PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol 2013;23:374-9. [PMID: 23578748 DOI: 10.1016/j.tcb.2013.03.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
146 Gasch C, Oldopp T, Mauermann O, Gorges TM, Andreas A, Coith C, Müller V, Fehm T, Janni W, Pantel K, Riethdorf S. Frequent detection of PIK3CA mutations in single circulating tumor cells of patients suffering from HER2-negative metastatic breast cancer. Mol Oncol 2016;10:1330-43. [PMID: 27491860 DOI: 10.1016/j.molonc.2016.07.005] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
147 Chen WT, Zhu G, Pfaffenbach K, Kanel G, Stiles B, Lee AS. GRP78 as a regulator of liver steatosis and cancer progression mediated by loss of the tumor suppressor PTEN. Oncogene. 2014;33:4997-5005. [PMID: 24141775 DOI: 10.1038/onc.2013.437] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
148 Yan Y, Wang Y, Tan Q, Hara Y, Yun TK, Lubet RA, You M. Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. Neoplasia 2006;8:52-8. [PMID: 16533426 DOI: 10.1593/neo.05652] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
149 Lim HJ, Crowe P, Yang JL. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. J Cancer Res Clin Oncol 2015;141:671-89. [PMID: 25146530 DOI: 10.1007/s00432-014-1803-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 89] [Article Influence: 10.8] [Reference Citation Analysis]
150 Dempsey DR, Viennet T, Iwase R, Park E, Henriquez S, Chen Z, Jeliazkov JR, Palanski BA, Phan KL, Coote P, Gray JJ, Eck MJ, Gabelli SB, Arthanari H, Cole PA. The structural basis of PTEN regulation by multi-site phosphorylation. Nat Struct Mol Biol 2021;28:858-68. [PMID: 34625746 DOI: 10.1038/s41594-021-00668-5] [Reference Citation Analysis]
151 Campos SM, Berlin S, Krasner CN, Whalen C, Atkinson T, Meegan K, Pereira L, Tyburski K, Lou W, Lee H, Horowitz N, Penson RT. A phase I study of AZD2171 and Temsirolimus in patients with advanced gynecological malignancies. Cancer Chemother Pharmacol 2022. [PMID: 35142863 DOI: 10.1007/s00280-022-04399-2] [Reference Citation Analysis]
152 Fantini D, Vascotto C, Deganuto M, Bivi N, Gustincich S, Marcon G, Quadrifoglio F, Damante G, Bhakat KK, Mitra S, Tell G. APE1/Ref-1 regulates PTEN expression mediated by Egr-1. Free Radic Res 2008;42:20-9. [PMID: 18324520 DOI: 10.1080/10715760701765616] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.0] [Reference Citation Analysis]
153 Kapoor A. Inhibition of mTOR in kidney cancer. Curr Oncol 2009;16 Suppl 1:S33-9. [PMID: 19478899 DOI: 10.3747/co.v16i0.419] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
154 Chen G, Park D, Magis AT, Behera M, Ramalingam SS, Owonikoko TK, Sica GL, Ye K, Zhang C, Chen Z, Curran WJ, Deng X. Mcl-1 Interacts with Akt to Promote Lung Cancer Progression. Cancer Res 2019;79:6126-38. [PMID: 31662324 DOI: 10.1158/0008-5472.CAN-19-0950] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
155 Rossi G, Russo A, Tagliamento M, Tuzi A, Nigro O, Vallome G, Sini C, Grassi M, Dal Bello MG, Coco S, Longo L, Zullo L, Tanda ET, Dellepiane C, Pronzato P, Genova C. Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient. Cancers (Basel) 2020;12:E1125. [PMID: 32365882 DOI: 10.3390/cancers12051125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
156 Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128:129-139. [PMID: 17218260 DOI: 10.1016/j.cell.2006.11.053] [Cited by in Crossref: 88] [Cited by in F6Publishing: 85] [Article Influence: 5.9] [Reference Citation Analysis]
157 Pachow D, Wick W, Gutmann DH, Mawrin C. The mTOR signaling pathway as a treatment target for intracranial neoplasms. Neuro Oncol 2015;17:189-99. [PMID: 25165193 DOI: 10.1093/neuonc/nou164] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
158 Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010;20:697-706. [PMID: 20578891 DOI: 10.1089/thy.2010.1646] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 14.9] [Reference Citation Analysis]
159 Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;2:45. [PMID: 19860903 DOI: 10.1186/1756-8722-2-45] [Cited by in Crossref: 158] [Cited by in F6Publishing: 148] [Article Influence: 12.2] [Reference Citation Analysis]
160 Kobar K, Collett K, Prykhozhij SV, Berman JN. Zebrafish Cancer Predisposition Models. Front Cell Dev Biol 2021;9:660069. [PMID: 33987182 DOI: 10.3389/fcell.2021.660069] [Reference Citation Analysis]
161 Liu YQ, Bai ZG, Ma XM, Zhang ZT. CDX2 inhibits invasion and migration of gastric cancer cells by phosphatase and tensin homologue deleted from chromosome 10/Akt signaling pathway. Chin Med J (Engl) 2015;128:1065-71. [PMID: 25881601 DOI: 10.4103/0366-6999.155092] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
162 Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin North Am. 2008;88:779-817, vii. [PMID: 18672141 DOI: 10.1016/j.suc.2008.05.002] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 5.9] [Reference Citation Analysis]
163 Zhou Y, Jia X, Wang G, Wang X, Liu J. PI-3 K/AKT and ERK signaling pathways mediate leptin-induced inhibition of PPARgamma gene expression in primary rat hepatic stellate cells. Mol Cell Biochem. 2009;325:131-139. [PMID: 19191008 DOI: 10.1007/s11010-009-0027-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
164 Sha SH, Chen FQ, Schacht J. PTEN attenuates PIP3/Akt signaling in the cochlea of the aging CBA/J mouse. Hear Res 2010;264:86-92. [PMID: 19761823 DOI: 10.1016/j.heares.2009.09.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
165 Baehring JM. Neuro-oncology in a nutshell. J Neurooncol 2004;70:271-2. [PMID: 15674485 DOI: 10.1007/s11060-004-5394-8] [Reference Citation Analysis]
166 Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X, Dolcet X. A novel three-dimensional culture system of polarized epithelial cells to study endometrial carcinogenesis. Am J Pathol 2010;176:2722-31. [PMID: 20395448 DOI: 10.2353/ajpath.2010.090974] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
167 Yang Z, Xie C, Xu W, Liu G, Cao X, Li W, Chen J, Zhu Y, Luo S, Luo Z, Lu N. Phosphorylation and inactivation of PTEN at residues Ser380/Thr382/383 induced by Helicobacter pylori promotes gastric epithelial cell survival through PI3K/Akt pathway. Oncotarget 2015;6:31916-26. [PMID: 26376616 DOI: 10.18632/oncotarget.5577] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 5.8] [Reference Citation Analysis]
168 Zhen L, Zhao Q, Lü J, Deng S, Xu Z, Zhang L, Zhang Y, Fan H, Chen X, Liu Z, Gu Y, Yu Z. miR-301a-PTEN-AKT Signaling Induces Cardiomyocyte Proliferation and Promotes Cardiac Repair Post-MI. Mol Ther Nucleic Acids 2020;22:251-62. [PMID: 33230431 DOI: 10.1016/j.omtn.2020.08.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
169 Hariri S, Rasti B, Mirpour M, Vaghar-lahijani G, Attar F, Shiri F. Structural insights into the origin of phosphoinositide 3-kinase inhibition. Struct Chem 2020;31:1505-22. [DOI: 10.1007/s11224-020-01510-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Tan WH, Baris HN, Burrows PE, Robson CD, Alomari AI, Mulliken JB, Fishman SJ, Irons MB. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007;44:594-602. [PMID: 17526801 DOI: 10.1136/jmg.2007.048934] [Cited by in Crossref: 175] [Cited by in F6Publishing: 131] [Article Influence: 11.7] [Reference Citation Analysis]
171 Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005;105:4477-83. [PMID: 15705789 DOI: 10.1182/blood-2004-09-3706] [Cited by in Crossref: 168] [Cited by in F6Publishing: 156] [Article Influence: 9.9] [Reference Citation Analysis]
172 Parikh C, Janakiraman V, Wu WI, Foo CK, Kljavin NM, Chaudhuri S, Stawiski E, Lee B, Lin J, Li H, Lorenzo MN, Yuan W, Guillory J, Jackson M, Rondon J, Franke Y, Bowman KK, Sagolla M, Stinson J, Wu TD, Wu J, Stokoe D, Stern HM, Brandhuber BJ, Lin K, Skelton NJ, Seshagiri S. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci U S A 2012;109:19368-73. [PMID: 23134728 DOI: 10.1073/pnas.1204384109] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 8.9] [Reference Citation Analysis]
173 Kaibori M, Shikata N, Sakaguchi T, Ishizaki M, Matsui K, Iida H, Tanaka Y, Miki H, Nakatake R, Okumura T. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Dig Dis Sci. 2015;60:919-928. [PMID: 25371154 DOI: 10.1007/s10620-014-3417-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
174 Alkafaji HA, Raji A, Rahman HS, Zekiy AO, Adili A, Jalili M, Hojjatipour T, Cid-Arregui A, Shomali N, Tarzi S, Tamjidifar R, Heshmati R, Marofi F, Akbari M, Hasanzadeh A, Deljavanghodrati M, Jarahian M, Sandoghchian Shotorbani S. Up-regulation of KISS1 as a novel target of Let-7i in melanoma serves as a potential suppressor of migration and proliferation in vitro. J Cell Mol Med 2021;25:6864-73. [PMID: 34096173 DOI: 10.1111/jcmm.16695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Zhu W, Zhu DS, Madan RA, Gulley JL, Figg WD, Dahut WL. Treatment of castration-resistant prostate cancer: updates on therapeutics targeting the androgen receptor signaling pathway. Am J Ther 2010;17:176-81. [PMID: 20019584 DOI: 10.1097/MJT.0b013e3181c6c0b2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
176 Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW, Liu XS. Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer. Nat Commun. 2016;7:10982. [PMID: 26975529 DOI: 10.1038/ncomms10982] [Cited by in Crossref: 187] [Cited by in F6Publishing: 189] [Article Influence: 31.2] [Reference Citation Analysis]
177 Redfern RE, Daou MC, Li L, Munson M, Gericke A, Ross AH. A mutant form of PTEN linked to autism. Protein Sci 2010;19:1948-56. [PMID: 20718038 DOI: 10.1002/pro.483] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
178 Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14. [PMID: 22322254 DOI: 10.1038/nrd3651] [Cited by in Crossref: 186] [Cited by in F6Publishing: 150] [Article Influence: 18.6] [Reference Citation Analysis]
179 Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, Seeger JM, Weiss J, Fischer F, Frommolt P, Michel K, Peifer M, Mermel C, Girard L, Peyton M, Gazdar AF, Minna JD, Garraway LA, Kashkar H, Pao W, Meyerson M, Thomas RK. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69:3256-61. [PMID: 19351834 DOI: 10.1158/0008-5472.CAN-08-4055] [Cited by in Crossref: 349] [Cited by in F6Publishing: 201] [Article Influence: 26.8] [Reference Citation Analysis]
180 Yasui M, Matsuoka S, Ueda M. PTEN hopping on the cell membrane is regulated via a positively-charged C2 domain. PLoS Comput Biol 2014;10:e1003817. [PMID: 25211206 DOI: 10.1371/journal.pcbi.1003817] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
181 Ryu JW, Choe SS, Ryu SH, Park EY, Lee BW, Kim TK, Ha CH, Lee SW. Paradoxical induction of growth arrest and apoptosis by EGF via the up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells. Oncotarget 2017;8:4181-95. [PMID: 27935858 DOI: 10.18632/oncotarget.13809] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
182 Chen J, Shao P, Cao Q, Li P, Li J, Cai H, Zhu J, Wang M, Zhang Z, Qin C, Yin C. Genetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population. PLoS One 2012;7:e40817. [PMID: 22815832 DOI: 10.1371/journal.pone.0040817] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
183 Galluzzi L, Pietrocola F, Bravo-San Pedro JM, Amaravadi RK, Baehrecke EH, Cecconi F, Codogno P, Debnath J, Gewirtz DA, Karantza V, Kimmelman A, Kumar S, Levine B, Maiuri MC, Martin SJ, Penninger J, Piacentini M, Rubinsztein DC, Simon HU, Simonsen A, Thorburn AM, Velasco G, Ryan KM, Kroemer G. Autophagy in malignant transformation and cancer progression. EMBO J. 2015;34:856-880. [PMID: 25712477 DOI: 10.15252/embj.201490784] [Cited by in Crossref: 695] [Cited by in F6Publishing: 698] [Article Influence: 99.3] [Reference Citation Analysis]
184 Lyu SM, Wu JY, Byun JY, Choi HY, Park SH, Choi YW. Expression of Phosphatase and Tensin Homologue, phospho-Akt, and p53 in Acral Benign and Malignant Melanocytic Neoplasms (Benign Nevi, Dysplastic Nevi, and Acral Melanomas). Ann Dermatol 2016;28:548-54. [PMID: 27746632 DOI: 10.5021/ad.2016.28.5.548] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
185 Cen P, Amato RJ. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther 2012;5:217-24. [PMID: 22870038 DOI: 10.2147/OTT.S16289] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
186 Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clin Cancer Res 2011;17:4474-83. [PMID: 21555373 DOI: 10.1158/1078-0432.CCR-10-2370] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
187 Rodríguez-Escudero I, Roelants FM, Thorner J, Nombela C, Molina M, Cid VJ. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast. Biochem J 2005;390:613-23. [PMID: 15913452 DOI: 10.1042/BJ20050574] [Cited by in Crossref: 70] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
188 Ren Y, Zhou X, Mei M, Yuan XB, Han L, Wang GX, Jia ZF, Xu P, Pu PY, Kang CS. MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol. BMC Cancer. 2010;10:27. [PMID: 20113523 DOI: 10.1186/1471-2407-10-27] [Cited by in Crossref: 137] [Cited by in F6Publishing: 129] [Article Influence: 11.4] [Reference Citation Analysis]
189 Youssef RF, Cost NG, Darwish OM, Margulis V. Prognostic markers in renal cell carcinoma: A focus on the 'mammalian target of rapamycin' pathway. Arab J Urol 2012;10:110-7. [PMID: 26558012 DOI: 10.1016/j.aju.2012.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
190 Bauer AJ, Stratakis CA. The lentiginoses: cutaneous markers of systemic disease and a window to new aspects of tumourigenesis. J Med Genet 2005;42:801-10. [PMID: 15958502 DOI: 10.1136/jmg.2003.017806] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
191 Wu J, Cang S, Liu C, Ochiai W, Chiao JW. Development of human prostate cancer stem cells involves epigenomic alteration and PI3K/AKT pathway activation. Exp Hematol Oncol 2020;9:12. [PMID: 32537260 DOI: 10.1186/s40164-020-00168-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
192 Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550-562. [PMID: 19629070 DOI: 10.1038/nrc2664] [Cited by in Crossref: 1656] [Cited by in F6Publishing: 1569] [Article Influence: 127.4] [Reference Citation Analysis]
193 Huang Z, Xing S, Liu M, Deng W, Wang Y, Huang Z, Huang Y, Huang X, Wu C, Guo X, Pan X, Jiang J, Feng F, Li T. MiR-26a-5p enhances cells proliferation, invasion, and apoptosis resistance of fibroblast-like synoviocytes in rheumatoid arthritis by regulating PTEN/PI3K/AKT pathway. Biosci Rep 2019;39:BSR20182192. [PMID: 31221815 DOI: 10.1042/BSR20182192] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
194 Ueno Y, Enokizono T, Fukushima H, Ohto T, Imagawa K, Tanaka M, Sakai A, Suzuki H, Uehara T, Takenouchi T, Kosaki K, Takada H. A novel missense PTEN mutation identified in a patient with macrocephaly and developmental delay. Hum Genome Var 2019;6:25. [PMID: 31149344 DOI: 10.1038/s41439-019-0056-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
195 Molinari F, Frattini M. Functions and Regulation of the PTEN Gene in Colorectal Cancer. Front Oncol. 2013;3:326. [PMID: 24475377 DOI: 10.3389/fonc.2013.00326] [Cited by in Crossref: 27] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
196 Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 2008;104:1124-49. [PMID: 18459149 DOI: 10.1002/jcb.21707] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 7.4] [Reference Citation Analysis]
197 Campos SM, Ghosh S. A current review of targeted therapeutics for ovarian cancer. J Oncol 2010;2010:149362. [PMID: 20069122 DOI: 10.1155/2010/149362] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 2.3] [Reference Citation Analysis]
198 Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010;16:1973-8. [PMID: 20215532 DOI: 10.1158/1078-0432.CCR-09-3182] [Cited by in Crossref: 76] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
199 Molhoek KR, Brautigan DL, Slingluff CL Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med 2005;3:39. [PMID: 16255777 DOI: 10.1186/1479-5876-3-39] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 4.8] [Reference Citation Analysis]
200 Pópulo H, Lopes JM, Soares P. The mTOR Signalling Pathway in Human Cancer. Int J Mol Sci. 2012;13:1886-1918. [PMID: 22408430 DOI: 10.3390/ijms13021886] [Cited by in Crossref: 424] [Cited by in F6Publishing: 403] [Article Influence: 42.4] [Reference Citation Analysis]
201 Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-52. [PMID: 21763970 DOI: 10.1016/j.hoc.2011.04.008] [Cited by in Crossref: 83] [Cited by in F6Publishing: 72] [Article Influence: 7.5] [Reference Citation Analysis]
202 Gu JJ, Fan KC, Zhang JH, Chen HJ, Wang SS. Suppression of microRNA-130b inhibits glioma cell proliferation and invasion, and induces apoptosis by PTEN/AKT signaling. Int J Mol Med 2018;41:284-92. [PMID: 29115407 DOI: 10.3892/ijmm.2017.3233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
203 Tian L, Fang YX, Xue JL, Chen JZ. Four microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitro. PLoS One. 2013;8:e75885. [PMID: 24098737 DOI: 10.1371/journal.pone.0075885] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 7.8] [Reference Citation Analysis]
204 Tsai CC, Chuang TW, Chen LJ, Niu HS, Chung KM, Cheng JT, Lin KC. Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells. World J Gastroenterol 2015; 21(14): 4169-4177 [PMID: 25892866 DOI: 10.3748/wjg.v21.i14.4169] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
205 Morgan TM, Koreckij TD, Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 2009;9:237-49. [PMID: 19275762 DOI: 10.2174/156800909787580999] [Cited by in Crossref: 182] [Cited by in F6Publishing: 163] [Article Influence: 14.0] [Reference Citation Analysis]
206 Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, Ono M. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Cancer Res 2010;70:8715-25. [PMID: 20959484 DOI: 10.1158/0008-5472.CAN-10-0043] [Cited by in Crossref: 114] [Cited by in F6Publishing: 64] [Article Influence: 9.5] [Reference Citation Analysis]
207 Xing D, Fadare O. Molecular events in the pathogenesis of vulvar squamous cell carcinoma. Semin Diagn Pathol 2021;38:50-61. [PMID: 33032902 DOI: 10.1053/j.semdp.2020.09.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
208 Cutillas PR, Khwaja A, Graupera M, Pearce W, Gharbi S, Waterfield M, Vanhaesebroeck B. Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry. Proc Natl Acad Sci U S A 2006;103:8959-64. [PMID: 16751276 DOI: 10.1073/pnas.0602101103] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
209 Yardley DA. Combining mTOR Inhibitors with Chemotherapy and Other Targeted Therapies in Advanced Breast Cancer: Rationale, Clinical Experience, and Future Directions. Breast Cancer (Auckl) 2013;7:7-22. [PMID: 23492649 DOI: 10.4137/BCBCR.S10071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 23] [Article Influence: 0.4] [Reference Citation Analysis]
210 Salvadori M. Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant 2012; 2(5): 74-83 [PMID: 24175199 DOI: 10.5500/wjt.v2.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
211 Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, Palanisamy N, Tomlins SA, Chinnaiyan AM, Shah RB. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009;22:1083-93. [PMID: 19407851 DOI: 10.1038/modpathol.2009.69] [Cited by in Crossref: 171] [Cited by in F6Publishing: 155] [Article Influence: 13.2] [Reference Citation Analysis]
212 Jane EP, Pollack IF. The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells. Cancer Lett 2008;268:46-55. [PMID: 18462865 DOI: 10.1016/j.canlet.2008.03.039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
213 Kim RH, Mak TW. Tumours and tremors: how PTEN regulation underlies both. Br J Cancer. 2006;94:620-624. [PMID: 16495927 DOI: 10.1038/sj.bjc.6602994] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 3.5] [Reference Citation Analysis]
214 Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 2005;7:134-53. [PMID: 15831232 DOI: 10.1215/S1152851704001115] [Cited by in Crossref: 385] [Cited by in F6Publishing: 236] [Article Influence: 22.6] [Reference Citation Analysis]
215 Xu X, Kobayashi S, Qiao W, Li C, Xiao C, Radaeva S, Stiles B, Wang RH, Ohara N, Yoshino T, LeRoith D, Torbenson MS, Gores GJ, Wu H, Gao B, Deng CX. Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. J Clin Invest 2006;116:1843-52. [PMID: 16767220 DOI: 10.1172/JCI27282] [Cited by in Crossref: 141] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
216 Sai X, Qin C, Wu Y, Zhao Y, Bian T. Downregulation of PTEN mediates bleomycin-induced premature senescence in lung cancer cells by suppressing autophagy. J Int Med Res 2020;48:300060520923522. [PMID: 32436415 DOI: 10.1177/0300060520923522] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
217 Amzel LM, Huang CH, Mandelker D, Lengauer C, Gabelli SB, Vogelstein B. Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 2008;8:665-9. [PMID: 18633356 DOI: 10.1038/nrc2443] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
218 Arnold HK, Sears RC. A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev 2008;27:147-58. [PMID: 18246411 DOI: 10.1007/s10555-008-9128-9] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.4] [Reference Citation Analysis]
219 Kyritsis AP, Bondy ML, Rao JS, Sioka C. Inherited predisposition to glioma. Neuro Oncol 2010;12:104-13. [PMID: 20150373 DOI: 10.1093/neuonc/nop011] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
220 Tzenaki N, Papakonstanti EA. p110δ PI3 kinase pathway: emerging roles in cancer. Front Oncol 2013;3:40. [PMID: 23459844 DOI: 10.3389/fonc.2013.00040] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
221 Martín-Pérez R, Palacios C, Yerbes R, Cano-González A, Iglesias-Serret D, Gil J, Reginato MJ, López-Rivas A. Activated ERBB2/HER2 licenses sensitivity to apoptosis upon endoplasmic reticulum stress through a PERK-dependent pathway. Cancer Res 2014;74:1766-77. [PMID: 24453000 DOI: 10.1158/0008-5472.CAN-13-1747] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
222 Schmeisser MJ, Kühl SJ, Schoen M, Beth NH, Weis TM, Grabrucker AM, Kühl M, Boeckers TM. The Nedd4-binding protein 3 (N4BP3) is crucial for axonal and dendritic branching in developing neurons. Neural Dev 2013;8:18. [PMID: 24044555 DOI: 10.1186/1749-8104-8-18] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
223 Stadler ME, Patel MR, Couch ME, Hayes DN. Molecular biology of head and neck cancer: risks and pathways. Hematol Oncol Clin North Am. 2008;22:1099-1124, vii. [PMID: 19010262 DOI: 10.1016/j.hoc.2008.08.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.5] [Reference Citation Analysis]
224 Angadi PV, Krishnapillai R. Evaluation of PTEN immunoexpression in oral submucous fibrosis: role in pathogenesis and malignant transformation. Head Neck Pathol 2012;6:314-21. [PMID: 22392409 DOI: 10.1007/s12105-012-0341-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
225 Zhu H, Han C, Lu D, Wu T. miR-17-92 cluster promotes cholangiocarcinoma growth: evidence for PTEN as downstream target and IL-6/Stat3 as upstream activator. Am J Pathol. 2014;184:2828-2839. [PMID: 25239565 DOI: 10.1016/j.ajpath.2014.06.024] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 8.2] [Reference Citation Analysis]
226 Sun RF, Yu QQ, Young KH. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies. Chronic Dis Transl Med 2018;4:29-44. [PMID: 29756121 DOI: 10.1016/j.cdtm.2018.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
227 Axanova LS, Chen YQ, McCoy T, Sui G, Cramer SD. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells. Prostate 2010;70:1658-71. [PMID: 20583132 DOI: 10.1002/pros.21201] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
228 Cheng SY. Thyroid hormone receptor mutations and disease: insights from knock-in mouse models. Expert Rev Endocrinol Metab 2007;2:47-57. [PMID: 30743748 DOI: 10.1586/17446651.2.1.47] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
229 Chen Z. The transrepression and transactivation roles of CtBPs in the pathogenesis of different diseases. J Mol Med (Berl) 2021. [PMID: 34196767 DOI: 10.1007/s00109-021-02107-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Nunes-Souza E, Silveira ME, Mendes MC, Nagashima S, de Paula CBV, Silva GGVCD, Barbosa GS, Martins JB, Noronha L, Lenzi L, Barbosa JRS, Donin RDF, Moura JF, Custódio G, Machado-Souza C, Lalli E, Figueiredo BC. From adrenarche to aging of adrenal zona reticularis: precocious female adrenopause onset. Endocr Connect 2020;9:1212-20. [PMID: 33112833 DOI: 10.1530/EC-20-0416] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Wey S, Luo B, Tseng CC, Ni M, Zhou H, Fu Y, Bhojwani D, Carroll WL, Lee AS. Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood 2012;119:817-25. [PMID: 21937694 DOI: 10.1182/blood-2011-06-357384] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 5.7] [Reference Citation Analysis]
232 Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE. Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Mol Cancer Ther 2015;14:1171-80. [PMID: 25695954 DOI: 10.1158/1535-7163.MCT-14-0708] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
233 Cattaneo M, Fontanella E, Canton C, Delia D, Biunno I. SEL1L affects human pancreatic cancer cell cycle and invasiveness through modulation of PTEN and genes related to cell-matrix interactions. Neoplasia 2005;7:1030-8. [PMID: 16331889 DOI: 10.1593/neo.05451] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
234 Chédeville AL, Madureira PA. The Role of Hypoxia in Glioblastoma Radiotherapy Resistance. Cancers (Basel) 2021;13:542. [PMID: 33535436 DOI: 10.3390/cancers13030542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
235 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
236 Garcia-Carracedo D, Turk AT, Fine SA, Akhavan N, Tweel BC, Parsons R, Chabot JA, Allendorf JD, Genkinger JM, Remotti HE, Su GH. Loss of PTEN expression is associated with poor prognosis in patients with intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2013;19:6830-6841. [PMID: 24132918 DOI: 10.1158/1078-0432.ccr-13-0624] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
237 Yang S, Zhou L, Reilly PT, Shen SM, He P, Zhu XN, Li CX, Wang LS, Mak TW, Chen GQ, Yu Y. ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation. Cell Death Dis 2016;7:e2082. [PMID: 26844697 DOI: 10.1038/cddis.2016.8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
238 Morris LG, Veeriah S, Chan TA. Genetic determinants at the interface of cancer and neurodegenerative disease. Oncogene 2010;29:3453-64. [PMID: 20418918 DOI: 10.1038/onc.2010.127] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 5.7] [Reference Citation Analysis]
239 Liu J, Hu J, Cheng L, Ren W, Yang M, Liu B, Xie L, Qian X. Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS. Onco Targets Ther 2016;9:557-65. [PMID: 26869800 DOI: 10.2147/OTT.S86966] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
240 Wan ML, Wang Y, Zeng Z, Deng B, Zhu BS, Cao T, Li YK, Xiao J, Han Q, Wu Q. Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways. Biosci Rep. 2020;40. [PMID: 32149326 DOI: 10.1042/bsr20200265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
241 Xing M. Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin North Am. 2008;41:1135-1146, ix. [PMID: 19040974 DOI: 10.1016/j.otc.2008.07.001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
242 Raghu P, Joseph A, Krishnan H, Singh P, Saha S. Phosphoinositides: Regulators of Nervous System Function in Health and Disease. Front Mol Neurosci 2019;12:208. [PMID: 31507376 DOI: 10.3389/fnmol.2019.00208] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
243 Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Med Oncol 2018;35:152. [PMID: 30291535 DOI: 10.1007/s12032-018-1212-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
244 Oviedo NJ, Pearson BJ, Levin M, Sánchez Alvarado A. Planarian PTEN homologs regulate stem cells and regeneration through TOR signaling. Dis Model Mech 2008;1:131-43; discussion 141. [PMID: 19048075 DOI: 10.1242/dmm.000117] [Cited by in Crossref: 67] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
245 Santra M, Chopp M, Santra S, Nallani A, Vyas S, Zhang ZG, Morris DC. Thymosin beta 4 up-regulates miR-200a expression and induces differentiation and survival of rat brain progenitor cells. J Neurochem 2016;136:118-32. [PMID: 26466330 DOI: 10.1111/jnc.13394] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
246 Man JH, Liang B, Gu YX, Zhou T, Li AL, Li T, Jin BF, Bai B, Zhang HY, Zhang WN, Li WH, Gong WL, Li HY, Zhang XM. Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells. J Clin Invest 2010;120:2829-41. [PMID: 20628200 DOI: 10.1172/JCI42542] [Cited by in Crossref: 46] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
247 Phadngam S, Castiglioni A, Ferraresi A, Morani F, Follo C, Isidoro C. PTEN dephosphorylates AKT to prevent the expression of GLUT1 on plasmamembrane and to limit glucose consumption in cancer cells. Oncotarget 2016;7:84999-5020. [PMID: 27829222 DOI: 10.18632/oncotarget.13113] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
248 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(4): 432-439 [DOI: 10.11569/wcjd.v13.i4.432] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Papakonstanti EA, Ridley AJ, Vanhaesebroeck B. The p110delta isoform of PI 3-kinase negatively controls RhoA and PTEN. EMBO J 2007;26:3050-61. [PMID: 17581634 DOI: 10.1038/sj.emboj.7601763] [Cited by in Crossref: 93] [Cited by in F6Publishing: 100] [Article Influence: 6.2] [Reference Citation Analysis]
250 Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 2006;20:1569-74. [PMID: 16778075 DOI: 10.1101/gad.1395006] [Cited by in Crossref: 191] [Cited by in F6Publishing: 189] [Article Influence: 11.9] [Reference Citation Analysis]
251 Witzig TE, Kaufmann SH. Inhibition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in hematologic malignancies. Curr Treat Options Oncol 2006;7:285-94. [PMID: 16916489 DOI: 10.1007/s11864-006-0038-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 4.1] [Reference Citation Analysis]
252 Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA, Arcaro A. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One 2012;7:e47109. [PMID: 23056595 DOI: 10.1371/journal.pone.0047109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
253 Cui Z, Gao H, Yan N, Dai Y, Wang H, Wang M, Wang J, Zhang D, Sun P, Qi T, Wang Q, Kang W, Jin X. LncRNA PlncRNA-1 accelerates the progression of prostate cancer by regulating PTEN/Akt axis. Aging (Albany NY) 2021;13:12113-28. [PMID: 33848262 DOI: 10.18632/aging.202919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Fu Y, Wey S, Wang M, Ye R, Liao CP, Roy-Burman P, Lee AS. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium. Proc Natl Acad Sci U S A 2008;105:19444-9. [PMID: 19033462 DOI: 10.1073/pnas.0807691105] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 9.7] [Reference Citation Analysis]
255 Kim J, Roh M, Doubinskaia I, Algarroba GN, Eltoum IE, Abdulkadir SA. A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene 2012;31:322-32. [PMID: 21685943 DOI: 10.1038/onc.2011.236] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
256 Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA, Barata JT. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 2008;118:3762-3774. [PMID: 18830414 DOI: 10.1172/jci34616] [Cited by in Crossref: 308] [Cited by in F6Publishing: 177] [Article Influence: 22.0] [Reference Citation Analysis]
257 Li C, Pu B, Gu L, Zhang M, Shen H, Yuan Y, Liao L. Identification of key modules and hub genes in glioblastoma multiforme based on co-expression network analysis. FEBS Open Bio 2021;11:833-50. [PMID: 33423377 DOI: 10.1002/2211-5463.13078] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Mohr R, Özdirik B, Knorr J, Wree A, Demir M, Tacke F, Roderburg C. In Vivo Models for Cholangiocarcinoma-What Can We Learn for Human Disease? Int J Mol Sci 2020;21:E4993. [PMID: 32679791 DOI: 10.3390/ijms21144993] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
259 Zhang X, Guo N, Jin H, Liu R, Zhang Z, Cheng C, Fan Z, Zhang G, Xiao M, Wu S, Zhao Y, Lu X. Bisphenol A drives di(2-ethylhexyl) phthalate promoting thyroid tumorigenesis via regulating HDAC6/PTEN and c-MYC signaling. J Hazard Mater 2021;425:127911. [PMID: 34910997 DOI: 10.1016/j.jhazmat.2021.127911] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Marbaniang C, Kma L. Dysregulation of Glucose Metabolism by Oncogenes and Tumor Suppressors in Cancer Cells. Asian Pac J Cancer Prev 2018;19:2377-90. [PMID: 30255690 DOI: 10.22034/APJCP.2018.19.9.2377] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
261 Langlois MJ, Bergeron S, Bernatchez G, Boudreau F, Saucier C, Perreault N, Carrier JC, Rivard N. The PTEN phosphatase controls intestinal epithelial cell polarity and barrier function: role in colorectal cancer progression. PLoS One. 2010;5:e15742. [PMID: 21203412 DOI: 10.1371/journal.pone.0015742] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 4.6] [Reference Citation Analysis]
262 Stojcev Z, Borun P, Hermann J, Krokowicz P, Cichy W, Kubaszewski L, Banasiewicz T, Plawski A. Hamartomatous polyposis syndromes. Hered Cancer Clin Pract. 2013;11:4. [PMID: 23724922 DOI: 10.1186/1897-4287-11-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
263 Jian B, Li Z, Xiao D, He G, Bai L, Yang Q. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 2016;37:8941-8949. [PMID: 26753960 DOI: 10.1007/s13277-015-4727-x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
264 Schiewer MJ, Den R, Hoang DT, Augello MA, Lawrence YR, Dicker AP, Knudsen KE. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer 2012;19:1-12. [PMID: 21903859 DOI: 10.1530/ERC-11-0072] [Cited by in Crossref: 30] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
265 Yang HP, Meeker A, Guido R, Gunter MJ, Huang GS, Luhn P, d'Ambrosio L, Wentzensen N, Sherman ME. PTEN expression in benign human endometrial tissue and cancer in relation to endometrial cancer risk factors. Cancer Causes Control 2015;26:1729-36. [PMID: 26376893 DOI: 10.1007/s10552-015-0666-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
266 Huang SJ, Huang J, Yan YB, Qiu J, Tan RQ, Liu Y, Tian Q, Guan L, Niu SS, Zhang Y, Xi Z, Xiang Y, Gong Q. The renoprotective effect of curcumin against cisplatin-induced acute kidney injury in mice: involvement of miR-181a/PTEN axis. Ren Fail 2020;42:350-7. [PMID: 32338107 DOI: 10.1080/0886022X.2020.1751658] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
267 Hörning M, Bullmann T, Shibata T. Local Membrane Curvature Pins and Guides Excitable Membrane Waves in Chemotactic and Macropinocytic Cells - Biomedical Insights From an Innovative Simple Model. Front Cell Dev Biol 2021;9:670943. [PMID: 34604207 DOI: 10.3389/fcell.2021.670943] [Reference Citation Analysis]
268 Yeo W, Chan SL, Mo FK, Chu CM, Hui JW, Tong JH, Chan AW, Koh J, Hui EP, Loong H, Lee K, Li L, Ma B, To KF, Yu SC. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer 2015;15:395. [PMID: 25962426 DOI: 10.1186/s12885-015-1334-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 64] [Article Influence: 7.9] [Reference Citation Analysis]
269 Rodríguez-Escudero I, Andrés-Pons A, Pulido R, Molina M, Cid VJ. Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations. J Biol Chem 2009;284:13373-83. [PMID: 19307184 DOI: 10.1074/jbc.M807867200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
270 Balciuniene J, Feng N, Iyadurai K, Hirsch B, Charnas L, Bill BR, Easterday MC, Staaf J, Oseth L, Czapansky-Beilman D, Avramopoulos D, Thomas GH, Borg A, Valle D, Schimmenti LA, Selleck SB. Recurrent 10q22-q23 deletions: a genomic disorder on 10q associated with cognitive and behavioral abnormalities. Am J Hum Genet 2007;80:938-47. [PMID: 17436248 DOI: 10.1086/513607] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
271 Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, Yu Y, Li H, Cai D, Sun Y, Chen H. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One. 2014;9:e88291. [PMID: 24533074 DOI: 10.1371/journal.pone.0088291] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 11.6] [Reference Citation Analysis]
272 Li Q, Bai Y, Lyle LT, Yu G, Amarasinghe O, Nguele Meke F, Carlock C, Zhang ZY. Mechanism of PRL2 phosphatase-mediated PTEN degradation and tumorigenesis. Proc Natl Acad Sci U S A 2020;117:20538-48. [PMID: 32788364 DOI: 10.1073/pnas.2002964117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
273 Harris LD, De La Cerda J, Tuziak T, Rosen D, Xiao L, Shen Y, Sabichi AL, Czerniak B, Grossman HB. Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog 2008;47:678-85. [PMID: 18288642 DOI: 10.1002/mc.20420] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
274 Larson SD, Jackson LN, Riall TS, Uchida T, Thomas RP, Qiu S, Evers BM. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 2007;204:764-73; discussion 773-5. [PMID: 17481480 DOI: 10.1016/j.jamcollsurg.2006.12.037] [Cited by in Crossref: 127] [Cited by in F6Publishing: 118] [Article Influence: 8.5] [Reference Citation Analysis]
275 Dai H, Li M, Yang W, Sun X, Wang P, Wang X, Su J, Wang X, Hu X, Zhao M. Resveratrol inhibits the malignant progression of hepatocellular carcinoma via MARCH1-induced regulation of PTEN/AKT signaling. Aging (Albany NY) 2020;12:11717-31. [PMID: 32530437 DOI: 10.18632/aging.103338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
276 Sacco A, Roccaro A, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. Oncotarget 2010;1:578-82. [PMID: 21317453 DOI: 10.18632/oncotarget.101105] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
277 LaPan P, Zhang J, Pan J, Hill A, Haney SA. Single cell cytometry of protein function in RNAi treated cells and in native populations. BMC Cell Biol 2008;9:43. [PMID: 18673568 DOI: 10.1186/1471-2121-9-43] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
278 Rangel N, Forero-Castro M, Rondón-Lagos M. New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response. Genes (Basel) 2017;8:E155. [PMID: 28587191 DOI: 10.3390/genes8060155] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
279 Ihle NT, Powis G. Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Mol Aspects Med 2010;31:135-44. [PMID: 20176047 DOI: 10.1016/j.mam.2010.02.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
280 Zhang X, Wu Y, Sun X, Cui Q, Bai X, Dong G, Gao Z, Wang Y, Gao C, Sun S, Ji N, Liu Y. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09275-z] [Reference Citation Analysis]
281 Gil A, Andrés-Pons A, Fernández E, Valiente M, Torres J, Cervera J, Pulido R. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 2006;17:4002-13. [PMID: 16807353 DOI: 10.1091/mbc.e06-05-0380] [Cited by in Crossref: 100] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
282 Monteiro AR, Hill R, Pilkington GJ, Madureira PA. The Role of Hypoxia in Glioblastoma Invasion. Cells 2017;6:E45. [PMID: 29165393 DOI: 10.3390/cells6040045] [Cited by in Crossref: 100] [Cited by in F6Publishing: 81] [Article Influence: 20.0] [Reference Citation Analysis]
283 Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res 2010;70:5305-15. [PMID: 20530665 DOI: 10.1158/0008-5472.CAN-09-3399] [Cited by in Crossref: 93] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
284 Yoo JY, Kang HB, Broaddus RR, Risinger JI, Choi KC, Kim TH. MIG-6 suppresses endometrial epithelial cell proliferation by inhibiting phospho-AKT. BMC Cancer 2018;18:605. [PMID: 29843645 DOI: 10.1186/s12885-018-4502-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
285 Imamura R, Tanaka R, Taniguchi A, Nakazawa S, Kato T, Yamanaka K, Namba-Hamano T, Kakuta Y, Abe T, Tsutahara K, Takao T, Kishikawa H, Nonomura N. Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. J Clin Med 2022;11:249. [PMID: 35011990 DOI: 10.3390/jcm11010249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Malaney P, Pathak RR, Xue B, Uversky VN, Davé V. Intrinsic disorder in PTEN and its interactome confers structural plasticity and functional versatility. Sci Rep 2013;3:2035. [PMID: 23783762 DOI: 10.1038/srep02035] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 7.1] [Reference Citation Analysis]
287 Ihle NT, Powis G. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Mol Cancer Ther 2009;8:1-9. [PMID: 19139107 DOI: 10.1158/1535-7163.MCT-08-0801] [Cited by in Crossref: 130] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
288 Nam S, Park T. Pathway-based evaluation in early onset colorectal cancer suggests focal adhesion and immunosuppression along with epithelial-mesenchymal transition. PLoS One 2012;7:e31685. [PMID: 22496728 DOI: 10.1371/journal.pone.0031685] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
289 Singh S, Srivastava P. Combined 3D QSAR Based Virtual Screening and Molecular Docking Study of Some Selected PDK-1 Kinase Inhibitors. Journal of Computational Medicine 2014;2014:1-12. [DOI: 10.1155/2014/563080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
290 Qi Y, Liu J, Chao J, Greer PA, Li S. PTEN dephosphorylates Abi1 to promote epithelial morphogenesis. J Cell Biol 2020;219:e201910041. [PMID: 32673396 DOI: 10.1083/jcb.201910041] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Dong M, Yang G, Liu H, Liu X, Lin S, Sun D, Wang Y. Aged black garlic extract inhibits HT29 colon cancer cell growth via the PI3K/Akt signaling pathway. Biomed Rep 2014;2:250-4. [PMID: 24649105 DOI: 10.3892/br.2014.226] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
292 Raja Singh P, Sugantha Priya E, Balakrishnan S, Arunkumar R, Sharmila G, Rajalakshmi M, Arunakaran J. Inhibition of cell survival and proliferation by nimbolide in human androgen-independent prostate cancer (PC-3) cells: involvement of the PI3K/Akt pathway. Mol Cell Biochem. 2017;427:69-79. [PMID: 28025797 DOI: 10.1007/s11010-016-2898-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
293 Meuillet EJ, Zuohe S, Lemos R, Ihle N, Kingston J, Watkins R, Moses SA, Zhang S, Du-Cuny L, Herbst R, Jacoby JJ, Zhou LL, Ahad AM, Mash EA, Kirkpatrick DL, Powis G. Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor. Mol Cancer Ther 2010;9:706-17. [PMID: 20197390 DOI: 10.1158/1535-7163.MCT-09-0985] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
294 Liu H, Cheng L, Cao D, Zhang H. Suppression of miR-21 Expression Inhibits Cell Proliferation and Migration of Liver Cancer Cells by Targeting Phosphatase and Tensin Homolog (PTEN). Med Sci Monit 2018;24:3571-7. [PMID: 29807978 DOI: 10.12659/MSM.907038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
295 Casar Tena T, Burkhalter MD, Philipp M. Left-right asymmetry in the light of TOR: An update on what we know so far. Biol Cell 2015;107:306-18. [PMID: 25943139 DOI: 10.1111/boc.201400094] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
296 Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN. Modulation in activation and expression of phosphatase and tensin homolog on chromosome ten, Akt1, and 3-phosphoinositide-dependent kinase 1: further evidence demonstrating altered phosphoinositide 3-kinase signaling in postmortem brain of suicide subjects. Biol Psychiatry 2010;67:1017-25. [PMID: 20163786 DOI: 10.1016/j.biopsych.2009.12.031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
297 Griguer CE, Oliva CR, Coffey CS, Cudkowicz ME, Conwit RA, Gudjonsdottir AL, Ecklund DJ, Fedler JK, Neill-hudson TM, Nabors LB, Benge M, Hackney JR, Chase M, Leonard TP, Patel T, Colman H, de la Fuente M, Chaudhary R, Marder K, Kreisl T, Mohile N, Chheda MG, Mcneill K, Kumthekar P, Dogan A, Drappatz J, Puduvalli V, Kowalska A, Graber J, Gerstner E, Clark S, Salacz M, Markert J. Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances 2022;4:vdab186. [DOI: 10.1093/noajnl/vdab186] [Reference Citation Analysis]
298 Atta IS. Study of the Association of Phosphatase and Tensin Homolog and p27 Expressions in Endometrial Hyperplasia and Carcinoma. J Microsc Ultrastruct 2019;7:109-16. [PMID: 31548921 DOI: 10.4103/JMAU.JMAU_54_18] [Reference Citation Analysis]
299 Azim H, Azim HA Jr, Escudier B. Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 2010;5:269-80. [PMID: 20563661 DOI: 10.1007/s11523-010-0141-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
300 Gowda C, Soliman M, Kapadia M, Ding Y, Payne K, Dovat S. Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia. Adv Biol Regul 2017;65:16-25. [PMID: 28623166 DOI: 10.1016/j.jbior.2017.06.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
301 Molina JR, Morales FC, Hayashi Y, Aldape KD, Georgescu MM. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. Cancer Res 2010;70:6697-703. [PMID: 20736378 DOI: 10.1158/0008-5472.CAN-10-1271] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
302 Huang G, Redelman-Sidi G, Rosen N, Glickman MS, Jiang X. Inhibition of mycobacterial infection by the tumor suppressor PTEN. J Biol Chem 2012;287:23196-202. [PMID: 22613768 DOI: 10.1074/jbc.M112.351940] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
303 Duman BB, Kara OI, Uğuz A, Ates BT. Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma. Contemp Oncol (Pozn) 2014;18:234-40. [PMID: 25258580 DOI: 10.5114/wo.2014.43803] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
304 Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F, Ciuffreda L. PTEN: Multiple Functions in Human Malignant Tumors. Front Oncol 2015;5:24. [PMID: 25763354 DOI: 10.3389/fonc.2015.00024] [Cited by in Crossref: 222] [Cited by in F6Publishing: 233] [Article Influence: 31.7] [Reference Citation Analysis]
305 Cobbs CS, Soroceanu L, Denham S, Zhang W, Britt WJ, Pieper R, Kraus MH. Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness. J Neurooncol 2007;85:271-80. [PMID: 17589804 DOI: 10.1007/s11060-007-9423-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.5] [Reference Citation Analysis]
306 Icard P, Loi M, Wu Z, Ginguay A, Lincet H, Robin E, Coquerel A, Berzan D, Fournel L, Alifano M. Metabolic Strategies for Inhibiting Cancer Development. Adv Nutr 2021;12:1461-80. [PMID: 33530098 DOI: 10.1093/advances/nmaa174] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
307 Colapietro A, Yang P, Rossetti A, Mancini A, Vitale F, Martellucci S, Conway TL, Chakraborty S, Marampon F, Mattei V, Gravina GL, Biordi AL, Wei D, Newman RA, Festuccia C. The Botanical Drug PBI-05204, a Supercritical CO2 Extract of Nerium Oleander, Inhibits Growth of Human Glioblastoma, Reduces Akt/mTOR Activities, and Modulates GSC Cell-Renewal Properties. Front Pharmacol 2020;11:552428. [PMID: 33013390 DOI: 10.3389/fphar.2020.552428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]